2422 related articles for article (PubMed ID: 7939169)
1. Antigens and antibodies in malignant melanoma.
Merimsky O; Shoenfeld Y; Chaitchik S; Yecheskel G; Fishman P
Tumour Biol; 1994; 15(4):188-202. PubMed ID: 7939169
[TBL] [Abstract][Full Text] [Related]
2. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
3. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
Ram M; Shoenfeld Y
Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
[TBL] [Abstract][Full Text] [Related]
4. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts.
Chen ZJ; Yang H; Ferrone S
J Immunol; 1991 Aug; 147(3):1082-90. PubMed ID: 1861071
[TBL] [Abstract][Full Text] [Related]
5. Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen.
Baharav E; Merimsky O; Altomonte M; Shoenfeld Y; Pavlovic M; Maio M; Ferrone S; Fishman P
Melanoma Res; 1995 Oct; 5(5):337-43. PubMed ID: 8541724
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
7. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.
Mittelman A; Chen ZJ; Yang H; Wong GY; Ferrone S
Proc Natl Acad Sci U S A; 1992 Jan; 89(2):466-70. PubMed ID: 1731316
[TBL] [Abstract][Full Text] [Related]
8. Modulation by adjuvants and carriers of the immunogenicity in xenogeneic hosts of mouse anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen.
Chen ZJ; Yang H; Liu CC; Hirai S; Ferrone S
Cancer Res; 1993 Jan; 53(1):112-9. PubMed ID: 8416734
[TBL] [Abstract][Full Text] [Related]
9. Idiotypic cascade in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies.
Yang H; Chen ZJ; Kageshita T; Yamada M; Ferrone S
Eur J Immunol; 1993 Jul; 23(7):1671-7. PubMed ID: 7686858
[TBL] [Abstract][Full Text] [Related]
10. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
11. In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody.
Stuhlmiller GM; Sullivan DC; Vervaert CE; Croker BP; Harris CC; Seigler HF
Ann Surg; 1981 Nov; 194(5):592-601. PubMed ID: 6895297
[TBL] [Abstract][Full Text] [Related]
12. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic MAb MK2-23. Immunohistochemical analysis of the reactivity of anti-anti-idiotypic MAb with surgically removed melanoma lesions.
Kageshita T; Hirai S; Ono T; Ferrone S
Int J Cancer; 1995 Jan; 60(3):334-40. PubMed ID: 7829240
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
Fishman P; Merimski O; Baharav E; Shoenfeld Y
Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
[TBL] [Abstract][Full Text] [Related]
14. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
15. Reactivity spectrum of 30 monoclonal antimelanoma antibodies to a panel of 28 melanoma and control cell lines.
Carrel S; Schreyer M; Schmidt-Kessen A; Mach JP
Hybridoma; 1982; 1(4):387-97. PubMed ID: 6208135
[TBL] [Abstract][Full Text] [Related]
16. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2.
Wang X; Ko EC; Peng L; Gillies SD; Ferrone S
Cancer Res; 2005 Aug; 65(15):6976-83. PubMed ID: 16061683
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-associated hypopigmentation: where are the antibodies?
Merimsky O; Shoenfeld Y; Baharav E; Altomonte M; Chaitchik S; Maio M; Ferrone S; Fishman P
Am J Clin Oncol; 1996 Dec; 19(6):613-8. PubMed ID: 8931683
[TBL] [Abstract][Full Text] [Related]
18. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H
J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the binding parameters to melanoma cells of antihuman high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies (mAb) and syngeneic anti-anti-idiotypic (anti-anti-id) mAb.
Chen ZJ; Ferrone S
Ann N Y Acad Sci; 1993 Aug; 690():398-401. PubMed ID: 8368768
[No Abstract] [Full Text] [Related]
20. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
